Dexamethasone

– The Trial Did Not Meet the Primary Endpoint of Progression-Free Survival (PFS) – – A Trend Favoring the Selinexor Arm was Observed with a 5.3 Month Improvement in Median PFS Relative to the Placebo Arm in the mITT Population; Company Plans to Continue to Follow Patients for Longer-Term Outcomes – – The Safety and Tolerability Profile was Consistent with the Known Profile of Selinexor; No New Safety Signals Were Observed – – Company Prioritizing its Resources on its Myelofibrosis and Multiple Myeloma Programs; Company to Reduce Planned Investment in Endometrial Cancer – NEWTON, Mass., July 30, 2026 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced topline results from its Phase 3 XPORT-EC-042 trial evaluating selinexor as a maintenance-only therapy compared to placebo in adult patients with TP53 wild-type advanced or recurrent endometrial cancer. The trial did not meet its primary endpoint of progression free survival. A trend favoring the selinexor arm was observed in the modified intent to treat (mITT) population (n=236), with a median PFS of 12.75 months in the selinexor arm compared to 7.43 months in the placebo arm (hazard ratio=0.76 [95% CI: 0.51, 1.12]; one-sided p-value=0.0791). The safety and tolerability profile of selinexor was consistent with its established safety profile, with no new safety signals observed. Karyopharm intends to complete a full evaluation of the data from the XPORT-EC-042 trial and plans to present the data at a future medical meeting. The results of the XPORT-EC-042 trial do not affect ongoing trials of selinexor in other potential indications. "These results are meaningful for a patient population lacking effective maintenance therapies that can delay disease progression," said Professor Ignace Vergote, MD, gynecologic oncologist at the Catholic University Leuven in Belgium, European Network for Gynaecological Oncological Trial groups (ENGOT) and global lead principal investigator. "The trend for a longer progression-free survival observed in the mITT population of the selinexor arm continues to highlight the potential of XPO1 inhibition in patients with TP53 wild-type/pMMR endometrial cancer." "Delaying the progression of cancer by five months at the median is a meaningful and encouraging outcome," said Dr. Robert Coleman, M.D., FACOG, FACS, of Texas Oncology and the Gynecologic Oncology Group (GOG) and lead principal investigator in the United States. "Although I am disappointed that the PFS improvement was not statistically significant, I look forward to continuing to follow these results over time and presenting the data from this important trial at an upcoming medical meeting. This patient population who have TP53 wild-type/pMMR advanced or recurrent endometrial cancer remains in need of new treatment options." "While disappointed by these unexpected results, we believe they advance the scientific understanding of XPO1 inhibition for tens of thousands of endometrial cancer patients worldwide. We are deeply committed to further investigating these data," said Reshma Rangwala, MD, PhD, Chief Medical Officer and Head of Research at Karyopharm. "I would like to thank all of the patients, their families and the clinical trial investigators and their staff, as well as ENGOT and GOG, for participating in this trial." "While the results we are announcing today fell short of our expectations, they do not diminish our confidence in the broader potential of selinexor and benefit of XPO1 inhibition," said Richard Paulson, President and Chief Executive Officer of Karyopharm. "We remain focused on maximizing our opportunity in myelofibrosis and continuing to build on our profitable multiple myeloma business. Looking ahead, we expect several important milestones in our myelofibrosis program over the next year, including the submission of our sNDA, the potential addition of selinexor to relevant compendia guidelines and topline data from the 60 mg cohort of the Phase 2 SENTRY-2 trial, each anticipated in the second half of 2026." About the Phase 3 XPORT-EC-042 Trial EC-042 (XPORT-EC-042; ENGOT-EN20; GOG-3083; NCT05611931) is a global, Phase 3, randomized, double-blind, placebo-controlled clinical trial evaluating selinexor as a maintenance-only therapy following chemotherapy or chemotherapy plus a checkpoint inhibitor in patients with TP53 wild-type advanced or recurrent endometrial cancer (N=257). Patients were randomized 1:1 to receive either a 60 mg, once-weekly, administration of oral selinexor or placebo until disease progression. The trial includes two patient populations, for which the primary endpoint of progression free survival was tested sequentially: 1) a modified intent to treat population (mITT) that includes patients with either, a) TP53 wild-type tumors with proficient mismatch repair status (pMMR); or, b) TP53 wild-type tumors with deficient mismatch repair status (dMMR), who are medically ineligible to receive checkpoint inhibitors; and, 2) the trial's original intent to treat (ITT) population, which includes all patients enrolled in the trial whose tumors are TP53 wild-type, regardless of MMR status. Overall survival is a key secondary endpoint. The mITT population enrolled 236 patients. As of the data cut-off, 106 progression free survival events as assessed by the investigator had been observed in the mITT population. In connection with the EC-042 trial, Karyopharm entered into a global collaboration with Foundation Medicine, Inc. to develop FoundationOne®CDx, a tissue-based comprehensive genomic profiling test to identify and enroll patients whose tumors are TP53 wild-type. The trial is being conducted in collaboration with the European Network of Gynaecological Oncological Trial groups (ENGOT) and the GOG Foundation, Inc. About Endometrial Cancer Endometrial cancer (EC) is the most common gynecologic malignancy in the U.S.1 In 2026, approximately 68,000 uterine cancers (predominantly endometrial) are expected to be diagnosed, with approximately 14,000 deaths.1 Worldwide there were about 420,368 cases with 97,723 deaths in 2022.2 Both incidence and mortality have continued to rise.3,4 Key risk factors include obesity, type 2 diabetes, high-fat diets, tamoxifen or oral estrogen use, and delayed menopause.5 TP53 is a well-recognized prognostic marker for EC; >50% of advanced or recurrent EC tumors are TP53wt (gene for tumor protein P53; wild-type), and ~40%-55% are both TP53wt and mismatch repair-proficient (pMMR).6-8 While immune checkpoint inhibitors have shown benefit in patients with mismatch repair–deficient (dMMR) and pMMR, the magnitude of benefit is greater for patients with dMMR tumors versus pMMR tumors.9-10 There remains an unmet need for targeted therapies for patients with pMMR EC.11 About XPOVIO® (selinexor) XPOVIO is a first-in-class, oral exportin 1 (XPO1) inhibitor compound for the treatment of cancer. XPOVIO functions by selectively binding to and inhibiting the nuclear export protein XPO1. XPOVIO is approved and marketed by Karyopharm in the U.S. in multiple oncology indications, including: (i) in combination with VELCADE® (bortezomib) and dexamethasone (XVd) in adult patients with multiple myeloma after at least one prior therapy; and (ii) in combination with dexamethasone in adult patients with heavily pre-treated multiple myeloma. XPOVIO® (also known as NEXPOVIO® in certain countries) has received regulatory approvals in various indications in a growing number of ex-U.S. territories and countries, including but not limited to the European Union, the United Kingdom, Mainland China, Taiwan, Hong Kong, Australia, South Korea, Singapore, Israel, and Canada. XPOVIO®/NEXPOVIO® is marketed in these respective ex-U.S. territories by Karyopharm's partners: Antengene, Menarini, Neopharm, and FORUS. Selinexor is also being investigated in several other mid- and late-stage clinical trials across multiple high-unmet need cancer indications. For more information about Karyopharm's products or clinical trials, please contact the Medical Information department at: Tel: +1 (888) 209-9326; Email: [email protected] XPOVIO® (selinexor) is a prescription medicine approved: In combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (XVd). In combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti‐CD38 monoclonal antibody (Xd). SELECT IMPORTANT SAFETY INFORMATION Warnings and Precautions Thrombocytopenia: Monitor platelet counts throughout treatment. Manage with dose interruption and/or reduction and supportive care. Neutropenia: Monitor neutrophil counts throughout treatment. Manage with dose interruption and/or reduction and granulocyte colony‐stimulating factors. Gastrointestinal Toxicity: Nausea, vomiting, diarrhea, anorexia, and weight loss may occur. Provide antiemetic prophylaxis. Manage with dose interruption and/or reduction, antiemetics, and supportive care. Hyponatremia: Monitor serum sodium levels throughout treatment. Correct for concurrent hyperglycemia and high serum paraprotein levels. Manage with dose interruption, reduction, or discontinuation, and supportive care. Serious Infection: Monitor for infection and treat promptly. Neurological Toxicity: Advise patients to refrain from driving and engaging in hazardous occupations or activities until neurological toxicity resolves. Optimize hydration status and concomitant medications to avoid dizziness or mental status changes. Embryo‐Fetal Toxicity: Can cause fetal harm. Advise females of reproductive potential and males with a female partner of reproductive potential, of the potential risk to a fetus and use of effective contraception. Cataract: Cataracts may develop or progress. Treatment of cataracts usually requires surgical removal of the cataract. Adverse Reactions The most common adverse reactions (≥20%) in patients with multiple myeloma who receive XVd are fatigue, nausea, decreased appetite, diarrhea, peripheral neuropathy, upper respiratory tract infection, decreased weight, cataract and vomiting. Grade 3‐4 laboratory abnormalities (≥10%) are thrombocytopenia, lymphopenia, hypophosphatemia, anemia, hyponatremia, and neutropenia. In the BOSTON trial, fatal adverse reactions occurred in 6% of patients within 30 days of last treatment. Serious adverse reactions occurred in 52% of patients. Treatment discontinuation rate due to adverse reactions was 19%. The most common adverse reactions (≥20%) in patients with multiple myeloma who receive Xd are thrombocytopenia, fatigue, nausea, anemia, decreased appetite, decreased weight, diarrhea, vomiting, hyponatremia, neutropenia, leukopenia, constipation, dyspnea, and upper respiratory tract infection. In the STORM trial, fatal adverse reactions occurred in 9% of patients. Serious adverse reactions occurred in 58% of patients. Treatment discontinuation rate due to adverse reactions was 27%. Use In Specific Populations Lactation: Advise not to breastfeed. For additional product information, including full prescribing information, please visit . To report SUSPECTED ADVERSE REACTIONS, contact Karyopharm Therapeutics Inc. at 1‐888‐209‐9326 or FDA at 1‐800‐FDA‐1088 or . About Karyopharm Therapeutics Karyopharm Therapeutics is a commercial-stage pharmaceutical company pioneering the science of nuclear export inhibition to develop differentiated therapies for patients with cancer. The Company's lead therapy, XPOVIO® (selinexor), is a first-in-class inhibitor of exportin 1 (XPO1). XPOVIO is marketed by the Company in the U.S. for adults with relapsed or refractory multiple myeloma and is approved as XPOVIO or NEXPOVIO® in more than 50 ex-U.S. countries and territories. Building on its leadership in XPO1 biology, Karyopharm is advancing selinexor's potential in hematological cancers, including in myelofibrosis. The Company is also exploring opportunities to evaluate XPO1 inhibition across myeloproliferative neoplasms using next-generation compounds, including eltanexor. Headquartered in Newton, Massachusetts, Karyopharm has an established, efficient, and scalable commercial infrastructure to bring novel therapeutic options to patients with cancer. For more information, visit and follow Karyopharm on LinkedIn and on X at @Karyopharm. Forward-Looking Statements This press release contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those regarding the ability of selinexor and eltanexor to treat patients with multiple myeloma, endometrial cancer, myelofibrosis, and other diseases; expectations with respect to the clinical development plans, regulatory discussions and potential regulatory submissions for selinexor; and expectations regarding the timing, presentation and publication of topline data, publications or compendia listings related to selinexor. Such statements are subject to numerous important factors, risks, and uncertainties, many of which are beyond Karyopharm's control, that may cause actual events or results to differ materially from Karyopharm's current expectations. For example, there can be no guarantee that Karyopharm will successfully commercialize XPOVIO or that any of Karyopharm's drug candidates, including selinexor, will successfully complete necessary clinical development phases or that development of any of Karyopharm's drug candidates will continue. Further, there can be no guarantee that any positive developments in the development or commercialization of Karyopharm's drug candidate portfolio will result in stock price appreciation. Management's expectations and, therefore, any forward-looking statements in this press release could also be affected by risks and uncertainties relating to a number of other factors, including the following: the adoption of XPOVIO in the commercial marketplace, the timing and costs involved in commercializing XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; the ability to obtain and retain regulatory approval of XPOVIO or any of Karyopharm's drug candidates that receive regulatory approval; Karyopharm's results of clinical trials and preclinical trials, including subsequent analysis of existing data and new data received from ongoing and future trials; the content and timing of decisions made by the U.S. Food and Drug Administration and other regulatory authorities, investigational review boards at clinical trial sites and publication review bodies, including with respect to the need for additional clinical trials; the ability of Karyopharm or its third party collaborators or successors in interest to fully perform their respective obligations under the applicable agreement and the potential future financial implications of such agreement; Karyopharm's ability to enroll patients in its clinical trials; unplanned cash requirements and expenditures; substantial doubt exists regarding Karyopharm's ability to continue as a going concern; development or regulatory approval of drug candidates by Karyopharm's competitors for products or product candidates in which Karyopharm is currently commercializing or developing; and Karyopharm's ability to obtain, maintain and enforce patent and other intellectual property protection for any of its products or product candidates. These and other risks are described under the caption "Risk Factors" in Karyopharm's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, which was filed with the Securities and Exchange Commission (SEC) on May 14, 2026, and in other filings that Karyopharm may make with the SEC in the future. Any forward-looking statements contained in this press release speak only as of the date hereof, and, except as required by law, Karyopharm expressly disclaims any obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise. XPOVIO® and NEXPOVIO® are registered trademarks of Karyopharm Therapeutics Inc. SOURCE Karyopharm Therapeutics Inc. 21% more press release views with Request a Demo

病例介绍 患者，女，61岁（初诊），因“发现右侧乳房肿物2月余”于2013年12月就诊。 月经史：已绝经。 既往史：无特殊。 家族史：无肿瘤家族史。 体格检查：右乳内象限可触及一肿物，2cm×1cm×1cm，边界不清，活动度较差。对侧乳腺未触及肿物，双侧腋窝及双侧锁骨上未触及肿大淋巴结。 影像学检查： 乳腺钼靶：右乳内上象限见不规则结节影，大小约12×10mm，分叶状，呈毛刺。 全腹彩超：未见肝脏占位。 胸部CT：未见肺部占位。 PET-CT：未见骨转移。 ECOG评分：0。 肿瘤标志物正常范围。 右乳肿物穿刺病理（2013年12月）：送检乳腺穿刺标本，符合乳腺浸润性癌，具体分型待免疫组化。 初步诊断：右乳浸润性癌（cT1N0M0，IA期） 治疗经过 手术及术后辅助治疗 2013年12月14日，患者于全麻下行右侧乳腺癌改良根治术。 术后病理（右乳）：乳腺浸润性导管癌，组织学分级2级，腋窝淋巴结1/14个见癌转移。 免疫组化：Ki67（40%+），ER（90%+，3+），PR（-），HER2（2+），FISH阴性。 术后诊断：右乳浸润性癌（pT1cN1M0，IIA期，Luminal B型）。 术后患者接受“EC-T”方案8周期化疗，后补充辅助放疗，并予依西美坦内分泌治疗，定期随访。 2020年4月24日随访复查： 乳腺+腋窝淋巴结彩超：右侧腋窝多发淋巴结，性质待定。 胸部磁共振：1、右侧腋下新增肿大淋巴结，转移瘤待除；2、左乳内上象限新增病灶，考虑不典型增生。 2020年4月28日行左乳+右腋窝穿刺术。穿刺病理（左乳）： 送检少量乳腺穿刺组织，见少量高级别导管原位癌。穿刺病理（右腋窝）：镜下见腺癌浸润。 诊断：1、右侧乳腺浸润性癌（rT1N3cM0，IIIc期）术后综合治疗后腋窝颈部淋巴结转移，分子分型：HR+/HER2-；2、左侧乳腺原位癌。 晚期一线治疗（2020.5.22-2023.2.21） 2020年5月22日起，患者接受“氟维司群+哌柏西利”内分泌治疗，治疗期间，患者的经过多次复查随访。 2023年2月9日随访复查发现：颈部淋巴结超声提示右侧颈后及锁骨上多发肿大淋巴结。 2023年3月3日随访复查：腹部磁共振提示肝右叶的外中部近包膜下占位性病变，考虑为转移瘤。 2023年2月17日行右锁骨上淋巴结穿刺术。 穿刺病理（右锁骨上淋巴结）： 穿刺活检组织，符合乳腺癌非特殊类型浸润性癌转移，组织学分级2级。 免疫组化：Ki67（30%+），ER（80%阳性，强），PR（1%阳性，弱），HER2（1+）。 诊断：1、右侧乳腺浸润性癌（rT1N3cM1，IV期）术后综合治疗后腋窝颈部淋巴结、肝、肺转移，分子分型：HR+/HER2低表达；2、左侧乳腺原位癌。 病例小结 患者初诊为HR+/HER2-（FISH阴性）早期乳腺癌，术后完成化疗、放疗及内分泌辅助治疗，获得6年多的长期无病生存；2020年首次复发后，基于CDK4/6抑制剂联合内分泌治疗疗效不劣于化疗且耐受性更佳的数据，我们为其选择氟维司群+哌柏西利一线方案，患者取得约33个月的PFS；当患者疾病再次进展时，我们果断对转移灶进行再活检，确认HER2由2+转为1+，精准锁定HER2低表达状态，并依据DB-04和DB-06研究的循证证据及国内外指南推荐，二线治疗换用T-DXd。治疗至今患者用药已超过39个月，且肝脏、颈部等转移灶全部消失，且全程未发生≥3级不良事件，尤其未出现间质性肺病，验证了T-DXd长期用药的安全性。 专家点评 该病例完整呈现了一例HR+/HER2低表达乳腺癌患者从初诊、手术、辅助治疗、首次复发、一线内分泌治疗长达33个月，到内分泌耐药后经T-DXd治疗获得超过39个月持续缓解，其中有几个关键点值得深入探讨。 一、初始治疗与长期随访的意义 患者2013年初诊为IIA期Luminal B型乳腺癌，接受规范的手术、化疗、放疗及内分泌治疗，获得了约7年的无病生存期（2013年至2020年）。这提示规范的综合治疗是延长患者生存的基础。2020年首次复发后，患者接受“氟维司群+哌柏西利”一线内分泌治疗，PFS达33个月，再次印证了CDK4/6抑制剂联合内分泌治疗在HR+晚期乳腺癌中的优异疗效。 二、精准分子分型指导治疗决策 患者在疾病进展后，及时对转移灶进行了再次穿刺活检，免疫组化显示HER2从最初的2+（FISH阴性）转变为1+，明确为HER2低表达。这一动态监测为后续治疗决策提供了关键依据。临床实践中，对于复发转移患者，建议对转移灶进行再次活检以明确当前分子分型，指导精准治疗。 三、T-DXd的长期疗效：从DB-04到DB-06，持续拓展获益边界 DB-04研究是全球首个针对HER2低表达乳腺癌并获得阳性结果的III期临床研究，奠定了T-DXd在HER2低表达晚期乳腺癌二线治疗的标准地位。在此基础上，DB-06研究进一步将治疗线数前移，聚焦于既往接受过1-2线内分泌治疗、但晚期阶段未接受过化疗的HR+/HER2低表达或超低表达晚期乳腺癌患者。DB-06研究结果显示，在HER2低表达人群中，T-DXd组中位PFS达13.2个月，而医生选择化疗组仅为8.1个月（HR=0.62，P＜0.001）；T-DXd组客观缓解率（ORR）达56.5%，化疗组为32.2%。在ITT人群中，T-DXd组中位PFS为13.2个月，化疗组为8.1个月（HR=0.63）。DB-06研究的阳性结果进一步拓展了T-DXd的获益人群，为内分泌经治、化疗未经治的HER2低表达晚期乳腺癌患者提供了全新的治疗选择。 本病例患者在一线氟维司群+哌柏西利治疗进展后，转移灶再活检提示HER2由2+转为1+，精准锁定HER2低表达状态。患者自2023年4月起接受T-DXd治疗，用药已超过39个月（截至目前已用药38个周期），且肝脏、颈部等转移灶全部消失，PFS远超临床研究的中位值。这充分说明在真实世界临床实践中，部分患者可从T-DXd治疗中获得持久且深度的疾病缓解。这一长期疗效的实现，既得益于T-DXd独特的作用机制——靶向HER2的ADC药物精准递送高活性载荷至肿瘤细胞，也与患者良好的体能状态和规范的治疗管理密不可分。 四、长期用药安全性的实践启示 T-DXd在带来卓越疗效的同时，其安全性管理不容忽视。本病例患者在接受T-DXd的治疗中，未发生≥3级不良事件，未出现ILD等需要停药的特殊不良事件，整体耐受性良好。这一真实世界的安全性数据验证了T-DXd长期用药的可行性和可控性。 值得注意的是，T-DXd的安全性管理需要建立全程化的监测体系。《德曲妥珠单抗临床管理路径及不良反应处理中国专家共识（2024版）》（以下简称共识）[3]为临床提供了全面的规范化管理方案。《共识》指出，在T-DXd治疗前，充分的与患者及主要照顾者的沟通可以帮助患者建立合理的治疗期望，加强对不良事件的警惕性，提高患者的用药依从性和配合疾病管理的协作性。对于恶心、呕吐等消化道反应，《共识》建议在输注后第2～4天继续预防性使用止吐措施。一般人群采用地塞米松联合5-HT3受体拮抗剂的二联预防方案，呕吐高危人群采用地塞米松联合5-HT3受体拮抗剂和NK1受体拮抗剂的三联预防方案。当患者合并使用可能导致便秘的药物时，建议患者摄入高膳食纤维的食物，当出现便秘的时候在下一治疗周期预防性使用缓泻剂。≥3级腹泻不良事件需中断T-DXd的使用，待恢复至≤1级时继续给药。恢复时间≤3天可维持原剂量继续给药，若恢复时间＞3天则需降低1个剂量水平继续给药。 对于ILD这一需要特别关注的不良事件，《共识》指出使用T-DXd治疗应加强对ILD/肺炎不良事件的监测，教育患者及时报告相关症状。1级ILD/肺炎不良事件应暂停T-DXd给药至恢复为0级，恢复时间≤28天可维持原剂量继续用药，恢复时间＞28天则应降低1个剂量水平继续用药。≥2级ILD/肺炎不良事件应永久停止使用T-DXd。发生2级ILD/肺炎不良事件时应立即开始皮质类固醇治疗［≥1 mg/（kg·d）泼尼松龙或等效药物］，持续≥14天，5天内没有改善应加强皮质类固醇剂量［2 mg/（kg·d）泼尼松龙或等效药物］或改为静脉注射甲泼尼龙。发生≥3级ILD/肺炎不良事件时应立即开始高剂量甲泼尼龙静脉注射治疗（500～1000 mg/天，持续3天），然后服用≥1 mg/（kg·d）的泼尼松龙（或等效物），持续≥14天，若5天内仍没有缓解，可考虑除激素外的其他疗法。 本病例的成功管理经验提示：T-DXd的长期用药安全性是可控的，关键在于“预防为主、早期识别、及时干预”的管理策略。在充分的不良事件预防和监测体系下，患者可以长期耐受T-DXd治疗并获得持续的临床获益。 ▌参考文献： [1] Modi S,Jacot W,Yamashita T,et al.Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer.N Engl J Med. 2022;387(1):9-20. doi:10.1056/NEJMoa2203690 [2] Yamashita T,Sohn JH,Tokunaga E,et al.Trastuzumab deruxtecan versus treatment of physician's choice in previously treated Asian patients with HER2-low unresectable/metastatic breast cancer:subgroup analysis of the DESTINY-Breast04 study.Breast Cancer.2024;31(5):858-868.doi:10.1007/s12282-024-01600-7 [3] 德曲妥珠单抗临床管理路径及不良反应处理共识专家组. 德曲妥珠单抗临床管理路径及不良反应处理中国专家共识（2024版）[J]. 中华肿瘤杂志, 2024, 46(4):304-318. DOI:10.3760/cma.j.cn112152-20231122-00319. 王瑞娟 教授 福建省立医院乳腺外科副主任医师、硕士生导师、教学主任 福建省海峡肿瘤防治科技交流协会乳腺肿瘤防治分会青委副主任委员 福建省海峡医药卫生交流协会乳腺肿瘤微无创分会常务委员 中国医药生物技术协会生物溶瘤专业委员会第一届常务委员 福建省肿瘤防治联盟专业委员会委员 福建省中西医结合学会普外科分会委员 福建省癌症康复协会专业委员会委员 主持多项省自然课题及厅青年课题 叶松青 教授 福州大学附属省立医院乳腺外科主任医师 中国抗癌协会乳腺癌专业委员会委员 中国临床肿瘤学会（CSCO）乳腺癌专家委员会委员 中国医师协会肿瘤医师分会乳腺癌学组委员 福建省医学会乳腺病学分会副主任委员 长江学术带乳腺联盟副主任委员 《福建卫生报》健康大使 《Gland Surgery》编委、《中华乳腺病杂志》编委、《中国肿瘤外科杂志》编委 （来源：《肿瘤瞭望》编辑部） 声 明 凡署名原创的文章版权属《肿瘤瞭望》所有，欢迎分享、转载。本文仅供医疗卫生专业人士了解最新医药资讯参考使用，不代表本平台观点。该等信息不能以任何方式取代专业的医疗指导，也不应被视为诊疗建议，如果该信息被用于资讯以外的目的，本站及作者不承担相关责任。